FDA Approves Columvi, Roche's Bispecific Antibody for Relapsed or Refractory Diffuse Large B-cell Lymphoma, Offering Fixed-Duration Treatment
Sunday, June 18, 2023
Roche, a pharmaceutical company, has recently obtained approval from the U.S. Food and Drug Administration (FDA) for its drug called Columvi® (glofitamab-gxbm). The FDA has granted accelerated approval for the use of Columvi in adult patients suffering from relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy. This approval was based on positive results from the phase I/II NP30179 study, which evaluated the response rate and durability of response. However, further confirmation of clinical benefit will be required through a confirmatory trial to maintain the approval. Columvi is expected to become available in the United States within the next few weeks.
DLBCL is a challenging and prevalent form of non-Hodgkin lymphoma in the United States. While many DLBCL patients respond well to treatment, those who experience relapse or do not respond adequately to subsequent therapies often face poor outcomes.
Dr. Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development, expressed the urgent need for additional treatment options for patients with relapsed or refractory DLBCL who have a poor prognosis. He believes that Columvi, as a fixed-duration treatment with durable response rates, has the potential to revolutionize the management of this aggressive lymphoma.
The approval of Columvi was based on encouraging findings from the phase I/II NP30179 study, which enrolled 132 DLBCL patients who had relapsed or were refractory to prior therapies. The study demonstrated that Columvi led to durable remission, with 56% of patients achieving an overall response and 43% achieving a complete response. Moreover, over two-thirds of responders maintained their response for at least nine months, and the median duration of response was 1.5 years. The most commonly reported adverse events associated with Columvi treatment included cytokine release syndrome, musculoskeletal pain, fatigue, and rash.
Columvi stands out as the first approved CD20xCD3 T-cell engaging bispecific antibody for the treatment of relapsed or refractory DLBCL. It is administered for a fixed period of 8.5 months, offering patients a specific treatment timeline and the possibility of a treatment-free interval. Additionally, Columvi is a chemotherapy-free treatment option that is readily available for infusion.
Roche is committed to advancing the field of CD20xCD3 T-cell engaging bispecific antibodies and has a comprehensive clinical development program in place. This program includes Columvi and another drug called Lunsumio® (mosunetuzumab). The company aims to explore the potential of these drugs as standalone therapies as well as in combination with other treatments to achieve long-lasting outcomes for patients. Furthermore, Roche is conducting phase III studies to assess the efficacy of these drugs in earlier stages of treatment.
Columvi has already received approval in Canada, and it has recently received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use, recommending its approval. Roche remains dedicated to developing innovative treatments for various blood diseases, both malignant and non-malignant conditions.
